跳转至内容
Merck
所有图片(1)

Key Documents

Y0001102

Teicoplanin

European Pharmacopoeia (EP) Reference Standard

别名:

Teicoplanin, Targocid, Teichomycin

登录查看公司和协议定价


About This Item

CAS号:
分類程式碼代碼:
41116107
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

teicoplanin

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

−20°C

InChI

1S/C88H97Cl2N9O33/c1-3-4-5-6-7-8-9-10-60(108)94-68-74(113)71(110)58(32-101)129-87(68)132-78-55-26-40-27-56(78)126-52-18-14-38(24-47(52)90)77(131-86-67(92-34(2)103)73(112)70(109)57(31-100)128-86)69-84(121)98-66(85(122)123)45-29-42(105)30-54(127-88-76(115)75(114)72(111)59(33-102)130-88)61(45)44-23-37(13-15-49(44)106)63(81(118)99-69)96-83(120)65(40)97-82(119)64-39-21-41(104)28-43(22-39)124-53-25-36(12-16-50(53)107)62(91)80(117)93-48(79(116)95-64)20-35-11-17-51(125-55)46(89)19-35/h11-19,21-30,48,57-59,62-77,86-88,100-102,104-107,109-115H,3-10,20,31-33,91H2,1-2H3,(H,92,103)(H,93,117)(H,94,108)(H,95,116)(H,96,120)(H,97,119)(H,98,121)(H,99,118)(H,122,123)/t48-,57-,58-,59-,62-,63-,64+,65-,66-,67-,68-,69+,70-,71-,72-,73-,74-,75+,76+,77-,86+,87+,88+/m1/s1

InChI 密鑰

BJNLLBUOHPVGFT-QRZIFLFXSA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Teicoplanin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化/生理作用

Teicoplanin is a glycopeptide antibiotic produced by Actinoplanes teichomiceticus that is effective against Gram-positive bacteria resistant to β-lactam antibiotics. Its mechanism of action is through inhibition of bacterial cell wall biosynthesis.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

F Menichetti
Journal of chemotherapy (Florence, Italy), 12 Suppl 5, 34-39 (2000-12-29)
The clinical and microbiological efficacy, cost-per-patient and tolerability of teicoplanin were compared with those of vancomycin as empirical or second-line treatment of febrile neutropenic episodes in patients with hematologic malignancy or solid tumors. In terms of efficacy and cost teicoplanin
F Parenti et al.
Journal of chemotherapy (Florence, Italy), 12 Suppl 5, 5-14 (2000-12-29)
The chemistry, microbiology and mode of action of teicoplanin, as well as the mechanism, control and epidemiology of glycopeptide resistance, are discussed in detail. The antibacterial activity of teicoplanin against Gram-positive bacteria, including those expressing resistance to unrelated compounds, is
S-H Hsiao et al.
Journal of clinical pharmacy and therapeutics, 35(6), 729-732 (2010-11-09)
Hypersensitivity syndrome associated with teicoplanin has rarely been reported. We report a case with a preceding episode of vancomyin-related neutropenia. A 47-year-old female with cervical spine infection was treated with vancomycin. Neutropenia occurred after 17 days of vancomycin therapy. Vancomycin
Mustafa Erkan Inanmaz et al.
Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 32(6), 752-756 (2014-03-29)
Implant-related chronic osteomyelitis is a serious complication of orthopedic surgery requiring implant removal and radical debridement. Extracorporeal shockwave (ESW) have demonstrated significant bactericidal effectiveness in vitro and effectiveness and safety were evaluated in an animal model of osteomyelitis. In this
Alexandre B Cavalcanti et al.
The Cochrane database of systematic reviews, (6)(6), CD007022-CD007022 (2010-06-18)
Vancomycin and teicoplanin are commonly used to treat gram-positive infections, particularly those caused by methicillin-resistant Staphylococcus aureus (MRSA). There is uncertainty regarding the effects of teicoplanin compared to vancomycin on kidney function with some previous studies suggesting teicoplanin is less

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门